Novel broad-spectrum antibiotic compound prioritized for development in fight against AMR

REVIVE webinar on 27 June:
Progressing an antibacterial drug discovery project – an SME perspective

New partnership to improve access to new antibiotics in low- and middle-income countries

Investing in GARDP
2024 to 2028

THE RACE IS ON
Together we can stay ahead of antibiotic resistance

The Global Antibiotic Research & Development Partnership (GARDP) accelerates the development and access of treatments for drug-resistant bacterial infections. Together with public, private and non-profit partners, GARDP works to preserve the power of antibiotics for generations to come.

Antibiotic resistance can affect anyone, anywhere

Antibiotic resistance occurs when bacteria change over time and no longer respond to treatment. It is already associated with nearly 5 million deaths per year, making it one of the world’s biggest killers.

 

Anyone Anywhere Gardp Homepage

A global crisis of antibiotic resistance

Global Crisis Photo 1

Antibiotic resistance has been identified as one of the top 10 global health threats by the World Health Organization.

Crowd Of People Walking Street Wearing Masks

Antibiotic resistance is spreading all over the world as a pandemic of drug-resistant infections.

Close Up Of Grandmother Holding Hands With Baby Granddaughter Playing Game Together

Low- and middle-income countries, and certain population groups like women and children are hit hardest.

Asian Girl Sleeping In Hospital Bed

If left unchecked, antibiotic resistance may make it too risky to carry out routine surgeries and other modern medical interventions.

GARDP is acting now to counter drug resistance and save lives

Developing new treatments for public health needs

GARDP is working to deliver on its 5by2025” initiative and to expand its portfolio with new treatments for bacterial infections that pose the greatest threat to human health.

Access to antibiotics for patients in need around the world

GARDP’s agreements with pharmaceutical and biotech companies have the potential to slash delays in access to antibiotics from decades to years.

Partnerships to revitalize antibiotic development

We engage with all key stakeholders from the get-go to coordinate efforts in the antibiotic pipeline to develop an ecosystem of antibiotic R&D and access.

Raising our voices to protect the #PowerOfAntibiotics